Chris Viehbacher, president of GlaxoSmithKline Plc's U.S. pharmaceuticals unit, talks with Bloomberg's Michael McKee from Philadelphia about the company's study of its Avandia diabetes drug. An analysis of a Glaxo patient trial found that Avandia users had twice as many cases of congestive heart failure, in which cardiac muscle damaged by a heart attack is less able to pump blood throughout the body. The report, released today in the New England Journal of Medicine, found that patients were at no greater risk of developing all types of heart disease when using Avandia. Congress is holding a hearing on the drug tomorrow. (Source: Bloomberg)